Program
emrusolmin
Also written as “TEV-56286”, “anle138b” and “TEV-56286 Test”.
Its studies are mostly in Multiple System Atrophy · Parkinson Disease, led by 2 companies.
Drug pageEmrusolmin: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Teva Pharmaceutical Industriesits history only | 53 open or running | phase 2since Aug 20, 2024 | Aug 20, 2024 | Jan 15, 2027phase 1 · NCT07674940 |
| MODAG | 30 open or running | phase 1since Dec 16, 2019 | Dec 16, 2019 | none ahead |
Also a collaborator on its studies: Aptuit and Quotient Sciences.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseTeva licensed it from MODAG, for worldwide rights.Announced Oct 26, 2021 · Source: Teva and MODAG (release), Oct 26, 2021
History and studies of MODAG only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 16, 2019First study: phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyFirst studyNCT04208152 · 68 enrolled · United Kingdom
- Dec 17, 2020Phase 1 study in Parkinson DiseaseNCT04685265 · 70 enrolled · United Kingdom
- Oct 26, 2021Teva licensed it from MODAGLicenseWorldwide rights · announced · Teva and MODAG (release)
- Jan 25, 2022Named emrusolminINNProposed as its International Nonproprietary Name in WHO's List 126 · before, TEV-56286
- Sep 4, 2022Phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT05532358 · 54 enrolled · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 MODAG leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05532358Parkinson Disease 4, Autosomal Dominant Lewy Body · United Kingdom | 1 | Completed | Jan 28, 2023 | 54 |
| NCT04685265Parkinson Disease · United Kingdom | 1 | Completed | Nov 7, 2022 | 70 |
| NCT04208152Parkinson Disease 4, Autosomal Dominant Lewy Body · United Kingdom | 1 | Completed | Aug 4, 2020 | 68 |
How it is read
Names in the registry
- “TEV-56286”, 4 entries
- “anle138b”, 2 entries
- “TEV-56286 Test”, 1 entry
- “TEV-56286 Reference”, 1 entry
- “anle138b (TEV-56286)”, 1 entry
Codes read as this program: TEV56286.
Conditions, from the studies’ own filings
- Multiple System Atrophy, 3 studies
- Parkinson Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.